NEW EVIDENCE: INJECTION RELATED INFECTIOUS DISEASE INCIDENCE AFFIRMS MEDICATION ASSISTED TREATMENT (MAT) WORSENING OPIOID CRISIS
If “proven” MAT works, per expert consensus, to reduce high-risk opioid use, why is injection-related disease surging the more it’s provided?
by Clark Miller
Published December 11, 2022
It’s been established that over years and decades of America’s increasingly lethal opioid crisis incidence of opioid injection related infectious disease, like endocarditis, has trended up as American Medicine’s “proven“, “gold standard” cure for high-risk opioid use has increased in availability and provision.
Young adults’ risk of dying from a devastating infection of the heart has doubled to tripled in the United States during the past two decades, a new study reports.
Researchers ascribe the increase in fatal heart infections to the growing number of people between 15 and 44 who are injecting opioid drugs.
“We found that people who inject drugs comprise a bigger percentage of the deaths from infective endocarditis, compared to 20 years ago,” said senior researcher Dr. Polydoros Kampaktsis, an assistant professor with Columbia University’s division of cardiology, in New York City.
It’s critical to understand the importance of this type of evidence
The more deaths mount, the more pressure mounts to divert public healthcare resources to the unvalidated medical model provision of addictive, diverted and abused substitute opioids. Perversely, tragically, and criminally, it seems, because it has been established that provision of American Medicine’s fix for American Medicine’s opioid crisis predicts, rather than harm reduction or saved lives, worsening of increasingly lethal epidemics.
That’s established partly because trends in opioid-related overdose deaths are not a meaningful measure of effectiveness of OST (MAT).
For reasons discussed in this post and additional posts – each post with detailed explanation linking to primary research and other sources.
There is no body of evidence with results that control for the most likely of confounding explanations for any slowing of mortality – increased availability and use of the OD death-reversing drug naloxone.
On analysis of the evidence, naloxone use – its reduction of deaths acting and measured directly, unlike presumed benefit from OST – directly accounts for all apparent changes (= decreases) in opioid-related overdose deaths. This result holds when results are available on a local level (e.g. here, here, here, and here) and when national data are examined.
Attributing benefit to OST requires evidence of reduced high-risk use of opioids.
When outcomes are critically analyzed, the evidence points consistently to provision of the medical model fix or “treatment” for problem opioid use worsening, not protective for, high-risk use and associated harms including opioid-related mortality. Because high-risk use, measured as non-lethal overdose incidence (eliminating the confounding, established effects of expanding naloxone use and campaigns) has increased nationally and consistently in multiple locales where data are available as dose of the medical cure increases.
As explained and established by multiple lines of evidence in this new post, emergence over past years of the potent opioid fentanyl in street economies of illicit opioid use does not qualify those invalidating results – fentanyl cannot explain away the failure of increased provision of the medical “treatment” to reduce high-risk opioid use
Another direct measure of high-risk use of opioids
is incidence of opioid injection-related infective disease, like endocarditis
Think about it – incidence of infective diseases caused by injection of opioids. That use of opioids is high-risk. If OST provides benefit to at-risk users, the mechanism is by reducing risk and associated problems related to opioid use.
Trends of decreased incidence of an injection-related infectious disease could be attributed to a variety of factors including: changes in public health, prevention, or medical interventions; decrease in high-risk opioid use including use by injection; clean needle exchanges; behavioral health treatments; others. Identifying the factor(s) any decreases could be confidently attributed to would require that multiple congruent, well-designed studies and other lines of evidence point to those factors and not others.
Increases in incidence, like those we’re seeing, are different. If increases of significant magnitude occur over the same time period that an intervention, like the medical OST fix, hypothesized to be a “treatment” or protective factor has also increased, then that constitutes strong evidence against that intervention as beneficial in reducing high-risk use.
As we would predict from everything we know about problem substance use and the failure of medical approaches to provide benefit for that non-medical problem, those diseases are increasing in prevalence.
More to come.